Literature DB >> 16732789

Critical management in patients with severe enterovirus 71 infection.

Jieh-Neng Wang1, Chih-Ta Yao, Cheng-Nan Yeh, Chao-Ching Huang, Shih-Min Wang, Ching-Chuan Liu, Jing-Ming Wu.   

Abstract

OBJECTIVE: The aim of this study was to analyze clinical details occurring in children with severe enterovirus 71 (EV71) infection and synthesize the critical care experience for patients with severe EV71 infection.
METHODS: A retrospective clinical, laboratory, and hemodynamic study was performed in a pediatric intensive care unit in a university hospital. From March 1998 to April 2000, seven consecutive pediatric patients with severe EV71 infection were retrospectively analyzed as the comparison group. From May 2000 to March 2003, eight consecutive patients with severe EV71 infection who had received the protocol therapy were enrolled as the study group. Detailed information about clinical treatment and pharmacological therapy was collected for comparison.
RESULTS: The clinical presentations and laboratory findings between the comparison and the study groups were not significantly different. The amount of intravenous fluid in the first 24 h was significantly higher in the comparison group (9.2+/-5.0 vs 4.9+/-1.3 mL/kg per h). More patients in the study group received low doses of dopamine infusion, patients in the comparison group received more epinephrine, and none of them received milrinone. The acute-stage and long-term survival rates were higher in the study group (100% vs 43%, 87% vs 29%).
CONCLUSION: Early cardiopulmonary support may prevent the vicious cycle of cardiopulmonary failure and improve the clinical outcome of severe EV71 infection. Milrinone may be the ideal inotropic agent for these patients. Echocardiography, a central line, and an arterial line could be an alternate method to replace direct intracardiac hemodynamic monitoring for guiding critical management.

Entities:  

Mesh:

Year:  2006        PMID: 16732789     DOI: 10.1111/j.1442-200X.2006.02198.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  17 in total

1.  Clinical and etiological characteristics of enterovirus 71-related diseases during a recent 2-year period in Korea.

Authors:  Wi-Sun Ryu; Byounghak Kang; Jiyoung Hong; Seoyeon Hwang; Jonghyun Kim; Doo-Sung Cheon
Journal:  J Clin Microbiol       Date:  2010-05-12       Impact factor: 5.948

2.  A case-control study of risk factors for severe hand-foot-mouth disease among children in Ningbo, China, 2010-2011.

Authors:  Tianchi Yang; Guozhang Xu; Hongjun Dong; Min Ye; Tianfeng He
Journal:  Eur J Pediatr       Date:  2012-04-19       Impact factor: 3.183

3.  The Effectiveness of Different Doses of Intravenous Immunoglobulin on Severe Hand, Foot and Mouth Disease: A Meta-Analysis.

Authors:  Wei Jiao; Si-Ran Tan; Yan-Feng Huang; Li-Hong Mu; Yang Yang; Yan Wang; Xue-E Wu
Journal:  Med Princ Pract       Date:  2019-01-15       Impact factor: 1.927

Review 4.  Enteroviral encephalitis in children: clinical features, pathophysiology, and treatment advances.

Authors:  Shikha Jain; Bhupeswari Patel; Girish Chandra Bhatt
Journal:  Pathog Glob Health       Date:  2014-07       Impact factor: 2.894

5.  Clinical characteristics and treatment of severe encephalitis associated with neurogenic pulmonary edema caused by enterovirus 71 in China.

Authors:  Yu-Cai Zhang; Xing-Wang Li; Xiao-Dong Zhu; Su-Yun Qian; Yun-Xiao Shang; Bi-Ru Li; Xiao-Lin Liu
Journal:  World J Emerg Med       Date:  2010

6.  Extracorporeal life support for treatment of children with enterovirus 71 infection-related cardiopulmonary failure.

Authors:  Sheng-Ling Jan; Shing-Jong Lin; Yun-Ching Fu; Ching-Shiang Chi; Chung-Chi Wang; Hao-Ji Wei; Yen Chang; Betau Hwang; Po-Yen Chen; Fang-Liang Huang; Ming-Chih Lin
Journal:  Intensive Care Med       Date:  2009-12-24       Impact factor: 17.440

7.  The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate.

Authors:  Yorihiro Nishimura; Noel P McLaughlin; Jieyan Pan; Sara Goldstein; Susan Hafenstein; Hiroyuki Shimizu; Jeffrey D Winkler; Jeffrey M Bergelson
Journal:  PLoS Pathog       Date:  2015-10-02       Impact factor: 6.823

Review 8.  Management of Viral Central Nervous System Infections: A Primer for Clinicians.

Authors:  P Brandon Bookstaver; Phillip L Mohorn; Ansal Shah; Lauren D Tesh; April M Quidley; Ravish Kothari; Christopher M Bland; Sharon Weissman
Journal:  J Cent Nerv Syst Dis       Date:  2017-05-01

9.  Risk factors for neurologic complications of hand, foot and mouth disease in the Republic of Korea, 2009.

Authors:  Seong Joon Kim; Jong-Hyun Kim; Jin-Han Kang; Dong Soo Kim; Ki Hwan Kim; Kyung-Hyo Kim; Young-Hoon Kim; Ju-Young Chung; Joong Hyun Bin; Da Eun Jung; Ji Hong Kim; Hwang Min Kim; Doo-Sung Cheon; Byung Hak Kang; Soon Young Seo
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

10.  Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak.

Authors:  Mong How Ooi; See Chang Wong; Anand Mohan; Yuwana Podin; David Perera; Daniella Clear; Sylvia del Sel; Chae Hee Chieng; Phaik Hooi Tio; Mary Jane Cardosa; Tom Solomon
Journal:  BMC Infect Dis       Date:  2009-01-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.